Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — Shareholder Meeting (November 2020)
23 slides from Monash Ivf's shareholder meeting presentation, Nov 26, 2020
Slide 1: 2020 Annual General Meeting
I\° Monash IVF Group | Leading the future of reproductive care Brave together = 2020 Annual General Meeting 26 November 2020
Slide 2: Disclaimer
Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 802 309) ("MF") (includingits subsidiaries, aliates and associated companies) and provides general background information about MVF's activities as at the date of this presentation. The information does not purport to
Slide 3: Chairman's Address
Mr. Richard Davis Chairman’s Address e ™@ Monash IVF Group
Slide 4: Board of Directors
IN Monash IVF Group Board of Directors CO Ke Richard Davis Neil Broekhuizen Josef Czyzewski Richard Henshaw - . y [es S \ | : Zita Peach Catherine West Michael Knaap Malik Jainudeen Company Seoretary A 2020 Annual General Meeting
Slide 5: Voting instructions
Voting instructions + Get a Voting Card Voting Card 1. Click the Get a Voting Card box on your screen 2. Enter your Shareholder or Proxy Details FullVote Partial vote and click Submit Details and Vote 3. When the Voting Card pops up, select either Full Vote or Partial Vote 4. Select your voting pref
Slide 6: How to Ask a Question
How to Ask a Question t? Click the Ask a Question box on your Ask a Question screen 2. Select the Item of Business your question relates to 8. Type your question in the space provided* 4. Click Submit Question Gvsstio 5. If you require Assistance, please call Link Market Services on 1800 990 363 *Pl
Slide 7: Summary
Summary Strong recovery following temporary IVF suspension experienced during Q4FY20; Business has emerged financially stronger, more resilient and with strong growth momentum; Exceptional contribution from our People and Doctors supporting the medical response to the Pandemic and volume rebound fro
Slide 8: Chairman's Address: Trading Update and Outlook
Chairman’s Address Trading Update Monash IVF Australia delivered a 23.1% increase in stimulated cycles” compared to pep in the period from 1 July to 31 October 2020, Monash IVF's Key Markets2 Market Share during October YTDis above the comparative period. Since the recommencement of IVF procedures i
Slide 9: Chairman's Address: Thank you
Chairman’s Address Thank you The Board wish to thank our investor shareholders for their continued support during the unprecedented challenges faced during Q4FY20; The Company is well positioned to grow earnings in FY21 and beyond considering the strong recovery of the Group following the Domestic I
Slide 10: CEO Presentation
Mr. Michael Knaap CEO Presentation e INN ™@ Monash IVF Group
Slide 11: Overview of Monash IVF
121 ARS N Monash IVF Overview of Monash IVF Group Medical Wolinics&8servicecentres ses. Specialists 103 Fertility Specialists ar Fertiuiry CENTRE 7 Australian States/Territories 2 Malaysian States Monash IVF Group 100! Diagnostic IN45 sonash ive S a mM arket Setemiisis 2 specialised laboratories (VI
Slide 12: Reported EBITDA adjusted
1. Reported EBITDA adjusted by $2.0m, Reported EBIT adjusted by $2.6m and Reported NPAT by $2.7m 2. EBITDA is a non-IFRS measure. EBITDA is defined as Earnings before interest, tax, depreciation and amortisation 3. FY20 includes impact from changes to AASB16 Lease accounting standard (EBITDA +7.2m,
Slide 13: Quarterly volume growth Q1FY20 to Q1FY21
• • • Q1FY20 Q2FY20 Q3FY20 Q4FY20 Q1FY21 30% 23.3% • 25% 20% • 15% 10% 5% 1.6% 0% -5% -4.8% -0.8% -10% • -15% -20% • -18.8% -25% • •
Slide 14: Volumes compared to prior comparative period
• Volumes compared to prior comparative period • • • • • • (1) Stimulated cycles are MBS items 13200/1
Slide 15: ARS Australia Operational Performance
ARS Australia Operational Performance Operational execution of our Strategic Pillars are driving the Gr Doctor Partnerships Implementation of multi-centre clinical trial to investigate new microinjection technology with progress made to commercialise during FY21; Sperm selection device developmentin
Slide 16: ARS Australia Operational Performance
ARS Australia Operational Performance cosine: erational execution of our Strategic Pillars are driving the Group's value proposition to its patients and key stakeholders * New “Brave Together” advertising campaign illustrates innovative marketing investment following “) the recommencement of service
Slide 17: Diagnostics Performance
Diagnostics Performance The Ultrasound business continued to be resilient and has operated throughout COVID-19 * Ultrasound clinics have remained open throughout the Pandemic period; * FY20 Scans volumes increased by 1.8% to 82,311 compared to pep and Non-invasive Pre-natal Testing (NIPT) increased
Slide 18: ARS International Performance
ARS International Performance Early signs of recovery in Kuala Lumpur activity is emerging following easing of Movement Control Orders (MCO) restrictions * Kuala Lumpur was heavily impacted by Movement Control Orders (MCO) effective 27 March resulting in a 58% decline in March to May stimulated cycl
Slide 19: Strategy & FY21 Trading Update
Mr. Michael Knaap ‘ " Strategy & | FY21 Trading Update e NN ™@ Monash IVF Group
Slide 20: The most admired fertility solutions provider in the world
e Hi Monash IVF Group The most admired fertility solutions provider in the world. Best in Class fertility solutions for all, diagnostics, genetics and pathology. 20 2020 Annual General Meeting Our Pillars Digital Our Outcomes Local & International e Market Share s Creation Our Principles Commitment
Slide 21: Stimulated cycles in Key Markets
• • • • • • (1) Stimulated cycles are MBS items 13200/1 (2) Key Markets are Victoria, New South Wales, Queensland, South Australia and Norther Territory
Slide 22: Change Picture
Change Picture (1) Key Markets are Victoria, New South Wales, Queensland, South Australia and Norther Territory
Slide 23: Slide 23
Monash IVF Group — Shareholder Meeting (November 2020) on 6ix